Slightly Increased Blood Clot Rates After AstraZeneca Shot: Study

The study published in The BMJ on Wednesday, stresses that the risk of such adverse events is considered low.

A large study in Denmark and Norway has found slightly increased rates of vein blood clots, including in the brain, among adults who had received their first dose of the Oxford-AstraZeneca COVID-19 vaccine, compared with expected rates in the general population. However, the study published in The BMJ on Wednesday, stresses that the risk of such adverse events is considered low. The researchers from University of Southern Denmark, and Norwegian Institute of Public Health, set out to compare rates of blood clots and related conditions after vaccination with the Oxford-AstraZeneca vaccine with those in the general populations of the two countries. The findings are based on 280,000 people aged 18-65 who received a first dose of the Oxford-AstraZeneca COVID-19 vaccine, known as Covishield in India, from February 2021 through to 11 March 2021 in Denmark and Norway.